Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and β-Caryophyllene Patch in Neck Pain

Humanitas Clinical and Research Center

Status and phase: Not yet enrolling; Phase 3

Conditions: Neck Pain

Treatments: Drug: Cannabidiol and β-Caryophyllene Patch; Device: Oxygen-Ozone Therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT06099171

OZLEVOTENS

Details and patient eligibility

About

The aim of this study is to compare the effectiveness of combined treatment with paravertebral oxygen-ozone injections and topical patches containing Cannabidiol and β-Caryophyllene in patients with neck pain by evaluating the following aspects:

• Reduction of pain
• Reduction of disability associated with neck pain

Full description

Neck pain is a significant public health burden worldwide, with a prevalence of 2,696.5 per 100,000, and a major cause of disability, responsible for 2.56% of all years lived with disability. Many potential therapeutic interventions are available for the treatment of neck pain, including conservative therapies, minimally invasive procedures and open surgery. In particular, oxygen-ozone percutaneous injections have been tested and have proven to be well tolerated with good clinical results.

Patch cutaneous formulated with cannabidiol and β-carophyllene (Levotens®) has proven to have muscle relaxant and anti-inflammatory effects in an animal models: The tests used allow to evaluate motor performance with reference to motor coordination skills (pole test), exploration (open field test) and resistance to continuous and accelerated movement (rotarod test). These motor skills are impaired in a pain associated inflammatory response condition such as that induced by LPS (lipopolysaccharide). The CBD and BCP-based Levotens® patch placed in the area where the inflammatory stimulus is administered allows the recovery of motor function in the three types of behaviors studied.

Previous data available demonstrate a muscle relaxant action of CBD applied topically through a patch in patients suffering from TMD.

This is a randomized, controlled, prospective evaluation comparing combined treatment with paravertebral oxygen-ozone injections and topical patches containing Cannabidiol and β-Caryophyllene with only OOT. The maximum study duration for each subject will be 6 months. A total of 52 patients will be enrolled. These patients will meet specific inclusion and exclusion criteria but can be generally characterized as patients with neck pain who have been unable to achieve satisfactory pain relief with previous conservative treatments The primary study objective is to determine whether combining Levotens® Patch with OOT could lead to better early pain control than OOT alone.

1. The primary study endpoint is to establish the improvement in NRS Pain at 14 days from the start of treatment.

2. Secondary objectives of this study are:

   • Improvement in NRS pain at 1, 2, 4, 12, 36 weeks,
   • Improvement in NDI at 1, 2, 4, 12, 36 weeks.

Enrollment: 52 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neck pain resulting from spinal pathology present for at least 1 month with or without brachial irradiation
• Cervical radiographic and/or MRI examination certifying the pathology of the spine
• Failure of previous conservative treatment (pharmacological or physiotherapy)
• Adults
• Signing of informed consent

Exclusion criteria

• Specific causes of neck pain (trauma, spinal deformity, fracture, neoplasia)
• Central or peripheral neurological signs
• Rheumatic diseases: diagnosis of rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis or arthritis secondary to other inflammatory diseases, chondrocalcinosis, Paget's disease or villonodular synovitis
• Neuromuscular disorders
• Presence of cognitive-behavioral deficit or psychiatric illness which, in the opinion of the investigator, could compromise patient safety or interfere with the evaluation of the effects of the treatment
• Surgery in the previous 6 months
• Cervical infiltrative treatments in the previous 4 months
• Use of orally administered systemic steroids within 2 weeks prior to screening
• Pregnant or breastfeeding women or women planning to become pregnant during the study participation period
• Known alcohol or drug dependence currently or within the past year

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

52 participants in 2 patient groups

Oxygen-Ozone Therapy plus Cannabidiol and ß-Caryophyllene Patch

Experimental group

Description:

The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections. For the fisrt 2 weeks of oxygen-ozone therapy patients will be asked to apply patches with local action based on Cannabidiol and ß-Caryophyllene for 8-24 hours/day for 5 days/week.

Treatment:

Device: Oxygen-Ozone Therapy

Drug: Cannabidiol and β-Caryophyllene Patch

Oxygen-Ozone Therapy

Active Comparator group

Description:

The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections.

Treatment:

Device: Oxygen-Ozone Therapy